Skip to main content
Erschienen in:

12.09.2018 | Original Article – Clinical Oncology

Treatment outcomes of intracranial germinoma: a retrospective analysis of 170 patients from a single institution

verfasst von: Xin Lian, Xiaorong Hou, Junfang Yan, Shuai Sun, Zheng Miao, Zhikai Liu, Weiping Wang, Jing Shen, Jie Shen, Ke Hu, Fuquan Zhang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To perform a retrospective analysis of patients with intracranial germinoma treated in our department to evaluate treatment outcomes and determine optimal treatment strategies.

Methods

We reviewed the treatment outcomes of 170 patients with intracranial germinoma who were treated in our department from January 1996 to January 2017. The median patient age was 15 years old. Among the patients, 56 (33%) were pathologically diagnosed, and 114 (67%) were diagnosed clinically. Various radiation fields and doses were used. Cerebrospinal fluid (CSF) and serum beta-human chorionic gonadotropin (β-HCG) levels were examined before treatment in 114 patients. Endocrinological evaluation was performed in 141 patients before and after treatment. A total of 38 patients received chemotherapy prior to radiotherapy (RT). The median follow-up time was 64.5 months (range 4–260.5 months).

Results

The 5- and 10-year overall survival (OS) rates were 94.5% and 91.3%, respectively. The relapse-free survival (RFS) rates at 5- and 10-years were 91.9% and 78.1%, respectively. Relapses occurred in 18 patients within 6 months–10 years. The spinal cord metastasis rate was 3.4% in patients with a localized lesion who did not receive spinal cord irradiation and 16.7% in patients with bifocal disease who were treated using whole ventricular irradiation (WVI) or whole brain radiotherapy (WBRT). Treatment failure did not occur in patients receiving chemoradiotherapy or in patients receiving three-dimensional conformal radiation therapy (3D-CRT)/intensity-modulated radiation therapy (IMRT). The RFS rate did not have a statistically significant correlation with the CSF/serum β-HCG level. After RT, 19.1% of the patients developed newly impaired pituitary function and required hormone replacement therapy.

Conclusions

WVI or WBRT+ primary boost (PB) is a sufficient irradiation field for localized intracranial germinoma, while patients with bifocal disease should undergo craniospinal irradiation (CSI), especially when treated with RT alone. CSF β-HCG is not a prognostic marker for intracranial germinomas. The treatment results of chemotherapy followed by reduced-dose RT are comparable to those of RT alone. IMRT is recommended for intracranial germinoma to improve the target volume accuracy and decrease the complications of RT.
Literatur
Zurück zum Zitat Aoyama H, Shirato H, Kakuto Y et al (1998) Pathologically-proven intracranial germinoma treated with radiation therapy. Radiother Oncol 47:201–205CrossRefPubMed Aoyama H, Shirato H, Kakuto Y et al (1998) Pathologically-proven intracranial germinoma treated with radiation therapy. Radiother Oncol 47:201–205CrossRefPubMed
Zurück zum Zitat Calaminus G, Kortmann R, Worch J et al (2013) SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-oncology 15:788–796. https://doi.org/10.1093/neuonc/not019 CrossRefPubMedPubMedCentral Calaminus G, Kortmann R, Worch J et al (2013) SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-oncology 15:788–796. https://​doi.​org/​10.​1093/​neuonc/​not019 CrossRefPubMedPubMedCentral
Zurück zum Zitat Joo JH, Park JH, Ra YS et al (2014) Treatment outcome of radiation therapy for intracranial germinoma: adaptive radiation field in relation to response to chemotherapy. Anticancer Res 34:5715–5721PubMed Joo JH, Park JH, Ra YS et al (2014) Treatment outcome of radiation therapy for intracranial germinoma: adaptive radiation field in relation to response to chemotherapy. Anticancer Res 34:5715–5721PubMed
Zurück zum Zitat Nakagawa K, Aoki Y, Akanuma A et al (1992) Radiation therapy of intracranial germ cell tumors with radiosensitivity assessment. Radiat Med 10:55–61PubMed Nakagawa K, Aoki Y, Akanuma A et al (1992) Radiation therapy of intracranial germ cell tumors with radiosensitivity assessment. Radiat Med 10:55–61PubMed
Zurück zum Zitat O’Neil S, Ji L, Buranahirun C et al (2011) Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation. Pediatr Blood Cancer 57:669–673. https://doi.org/10.1002/pbc.23146 CrossRef O’Neil S, Ji L, Buranahirun C et al (2011) Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation. Pediatr Blood Cancer 57:669–673. https://​doi.​org/​10.​1002/​pbc.​23146 CrossRef
Zurück zum Zitat Shin KH, Kim IH, Choe G (2001) Impacts of elevated level of hCG in serum on clinical course and radiotherapy results in the histology-confirmed intracranial germinomas. Acta Oncol 40:98–101CrossRefPubMed Shin KH, Kim IH, Choe G (2001) Impacts of elevated level of hCG in serum on clinical course and radiotherapy results in the histology-confirmed intracranial germinomas. Acta Oncol 40:98–101CrossRefPubMed
Metadaten
Titel
Treatment outcomes of intracranial germinoma: a retrospective analysis of 170 patients from a single institution
verfasst von
Xin Lian
Xiaorong Hou
Junfang Yan
Shuai Sun
Zheng Miao
Zhikai Liu
Weiping Wang
Jing Shen
Jie Shen
Ke Hu
Fuquan Zhang
Publikationsdatum
12.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2743-0

Weitere Artikel der Ausgabe 3/2019

Journal of Cancer Research and Clinical Oncology 3/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.